Aktuelle Publikationen der GBG
Originalarbeiten 2010
Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S: Effect of neoadjuvant anthracycline-taxane based chemotherapy in different biological breast cancer phenotypes – Overall results from the GeparTrio study. Breast Cancer Res Treat. 2010 Aug 10. [Epub ahead of print]
Kaufmann M, Maass N, Costa S.D, Schneeweiss A, Loibl S, Suetterlin M, Schrader I, Gerber B, Bauer B, Wiest W, Tomé O, Distelrath A, Hagen V, Kleine-Tebbe A, Ruckhaeberle E, Mehta K, von Minckwitz G: First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial. Eur J Cancer. 2010 Aug 24. [Epub ahead of print]
von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, Kreienberg R, Hilfrich J, Gerber B, Hanusch C, Fehm T, Strumberg D, Solbach C, Nekljudova V, Untch M; for the German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie--Brust investigators: Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol. 2010 Jul 12. [Epub ahead of print]
Witzel I, Loibl S, von Minckwitz G, Mundhenke C, Huober J, Hanusch C, Henschen S, Hauschild M, Lantzsch T, Tesch H, Latos K, Just M, Hilfrich J, Barinoff J, Eulenburg CZ, Roller M, Untch M, Müller V: Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res Treat. 123(2):437-45, 2010
Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M: Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study. J Clin Oncol. 10;28(17):2874-80, 2010
Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N, Coleman R: Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010 May 5. [Epub ahead of print]
Scientific Board, Harbeck N, von Minckwitz G, Thürlimann B: Bisphosphonates in adjuvant treatment of early breast cancer. Crit Rev Oncol Hematol 74 Suppl 1:S1, 2010
Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K: Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 16(9):2634-45, 2010
Untch M, Rezai M, Loibl S, Fasching P.A, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer J.U, Thomssen C, Costa S.D, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G for the German Breast Group and AGO Breast Group: Neoadjuvant Treatment with Trastuzumab in HER2-positive Breast Cancer: Results from GeparQuatro Study. J Clin Oncol 28(12):2024-31, 2010
von Minckwitz G, Rezai M, Loibl S, Fasching P.A, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch K, Kühn T, du Bois A, Blohmer J.U, Thomssen C, Costa S.D, Jackisch C, Kaufmann M, Mehta K, Untch M: Capecitabine in Addition to Anthracycline / Taxane-based Neoadjuvant Treatment in Patients with Primary Breast Cancer: The Phase III GeparQuattro Study. J Clin Oncol. 28(12):2015-23, 2010
Denkert C, Loibl S, Noske A, Roller M, Müller B, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G: Tumor-associated Lymphocytes as an Independent Predictor of Response to Neo-adjuvant Chemotherapy in Breast Cancer. J Clin Oncol 28(1):105-13, 2010
Eiermann W, Graf E, Ataseven B, Conrad B, Hilfrich J, Massinger-Biebl H, Vescia S, Loibl S, von Minckwitz G, Schumacher M, Kaufmann M; for the German Adjuvant Breast Cancer Group: Dose-intensifed epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph npdes: Results of a randomised trial (GABG-IV E-93) - The German Adjuvant Breast Cancer Group. Eur J Cancer 46(1):84-94, 2010
Review / Article 2010
Lea Studie: Vorteile durch Angiogenesehemmer in Kombination mit antihormoneller Therapie? www.mammamia-online.de, April bis Juni 2010
Sehouli J, Goertz A, Steinle T, Dubois R, Plesnila-Frank C, Lalla A, von Minckwitz G: Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany. Dtsch Med Wochenschr. 135(9):385-9, 201
Kaufmann M, Morrow M, von Minckwitz G, Harris JR; Biedenkopf Expert Panel Members: Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel. Cancer 116(5):1184-91, 2010
Kongressbeiträge 2010 (Abstracts, Poster, Präsentationen)
ASCO 2010
von Minckwitz G: ICE II: An investigational randomized phase II study on epirubicin (E) plus cyclophospamide(C) (or CMF) vs. nab-paclitaxel plus capecitabine (PX) as adjuvant chemotherapy for elderly non frail patients with an increased risk for relapse of a primary carcinoma of the breast. J Clin Oncol 28(15S):8s, 2010 (suppl; abstr TPS 104) , ASCO 2010
Kühn T, Bauerfeind I, Fehm T, Fleige B, Helms G, Liedtke C, Mai M, von Minckwitz G, Staebler A, Untch M: Sentinel-node biopsy before or after neoadjuvant systemic treatment: The German SENTINA trial. J Clin Oncol 28(15S):10s, 2010 (suppl; abstr TPS 114), ASCO 2010
von Minckwitz G, Untch M, Nüesch E, Kaufmann M, Kümmel S, Fasching P, Eiermann W, Blohmer J.U, Loibl S, Jüni P for the GBG and AGO study groups: Impact of treatment characteristics on response of different breast cancer subtypes: pooled multi-layer analysis of the German neo-adjuvant chemotherapy trials. J Clin Oncol 28(15s):68s, 2010 (suppl; abstr 501), ASCO 2010
Kaufmann M, Eiermann W, Schütte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Loibl S, Nekljudova V, von Minckwitz G: Long term results form the neoadjuvant GeparDuo trial comparing a dose-dense regimen of adriamycin and docetaxel (ADoc) with a standard regimen of adriamycin / cyclophosphamide followed by docetaxel (AC–Doc) in patients (pts) with operable breast cancer (BC). J Clin Oncol 28(15s):76s, 2010 (suppl; abstr 537), ASCO 2010
Thomssen C, Kantelhardt E.J, Plueckhahn K, Veyret C, Augustin D, Hanf V, Paepke D, Meisner C, von Minckwitz G, Harbeck N, On behalf of the NNBC-3 Europe study group: Report of toxicities from the multicentre, randomised NNBC 3-europe trial: 6xFEC versus 3xFEC – 3xDoc for high-risk node-negative breast cancer patients. J Clin Oncol 28(15s):80s, 2010 (suppl; abstr 554)
Loibl S, Müller B, von Minckwitz G, Blohmer J.U, du Bois A, Huober J, Fend F, Budczies J, Denkert C on behalf of the German Breast Group: PARP expression in early breast cancer and its predictive value for response to neoadjuvant chemotherapy. J Clin Oncol 28(15s):725s, 2010 (suppl; abstr 10511), ASCO 2010
Darb-Esfahani S, von Minckwitz G, Gehrmann M, Kronenwett R, Denkert C, Budczies J, Rody A, Kuemmel S: Identification of thymosin beta 15 A (TMSB15A) mRNA expression as a predictor for response to neoadjuvant chemotherapy in patients with operable breast cancer. J Clin Oncol 28(15s):726s, 2010 (suppl; abstr 10514), ASCO 2010
E. J. Kantelhardt, C. Thomssen, M. Vetter, C. Meisner, M. Schmidt, P. Martin, F. Sweep, G. Von Minckwitz, M. Schmitt, N. Harbeck, On behalf of the NNBC 3-Europe study group.; Molecular types and prognostic markers uPA/PAI-1 for 2,497 early breast cancer patients in the multicenter, randomized NNBC 3-Europe trial. J Clin Oncol 28(15s):732s, 2010 (suppl; abstr 10539), ASCO 2010
EBCC 2010
Witzel I, Müller V, Loibl S, Fehm T, von Minckwitz G, Eidtmann H, Conrad U, Roller M, zu Eulenburg C, Untch M: Monitoring serum HER2 levels in the neoadjuvant „Geparquattro“ trial-a decrease predicts pathological complete remission. Eur J Cancer 8(3):61, 2010, Poster discussion / Abstract # 12
von Minckwitz G, Zahm MD, Eidtmann H, Tesch H, du Bois A, Schwedler K, Hilfrich J, Jackisch C, Mehta K, Gerber B: Zoledronic acid (ZOL) as add on therapy in patients with tumor residuals after neoadjuvant chemotherapy for primary breast cancer – first interim safety analysis of the NATAN study (GBG 36). Eur J Cancer 8(3):65, 2010, Poster / Abstract # 24
Loibl S, Conrad B, Warm M, Schwedler K, Gerber B Schrader I, Eidtmann H, Linder M, Mehta K, von Minckwitz G: SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) + sorafenib (S) followed by paclitaxel (Pw) + sorafenib (S) in women with previously untreated primary breast cancer (BC) (GBG 45). Eur J Cancer 8(3):91, 2010, Poster / Abstract # 111
von Minckwitz G, Müller B, Loibl S, Blohmer J.U, du Bois A, Huober J, Kandolf R, Budczies J, Denkert C: PARP is expressed in all subtypes of early breast cancer and is a predictive factor for response to neoadjuvant chemotherapy. Eur J Cancer 8(3):188, 2010, Proffered paper oral / Abstract # 443
Loibl S, Bontenbal M, Ring A, Kaufmann M, Crivellari D, Fehm T, Heinrigs M, Lenhard M, Mehta K, von Minckwitz G: Breast cancer during pregnancy – a prospective and retrospective European registry (GBG-20/BIG02-03). Eur J Cancer 8(3):205, 2010, Poster discussion / Abstract # 499
DKK 2010
Gerber B, von Minckwitz G, Stehle H, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B, Mehta K, Loibl S: ZORO: A prospective randomized multicenter study to prevent chemotherapy induced ovarian failure with the GnRH-Agonist Goserelin in young hormone insensitive breast cancer patients receiving anthracycline containing (neo-)adjuvant chemotherapy. . Internal Journal for Cancer Research and Treatment 33, Supplement 2, Page 118, Abstrct # PO538, DKK 2010, Berlin
Loibl S, Conrad B, Warm M, Schwedler K, Gerber B, Schrader I, Eidtmann H, Magnani D, Mehta K, von Minckwitz G: SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) + sorafenib followed by paclitaxel (P) + sorafenib in women with previously untreated primary breast cancer. Internal Journal for Cancer Research and Treatment 33, Supplement 2, Page 118, Abstrct # PO537, DKK 2010, Berlin
Vetter M, Thomssen C, kantelhardt E, Geurts-Moespot A, Schmidt M, Veyret C, Meisner C, von Minckwitz G, Hanf V, Martin P, Schmitt M, Sweep F, Harbeck N: Die Bestimmung der prognostischen Faktoern uPA und PAI 1 zur Risikoevaluation beim nodalnegativen Mammakarzinom-Erfahrungen der NNBC3-Europe Studie. Internal Journal for Cancer Research and Treatment 33, Supplement 2, Page 25, Abstrct # FV110, DKK 2010, Berlin
DGP 2010
Müller B, Loibl S, Darb Esfahani S, Solbach C, Budczis J, Lichtenegger W, Dietel M, Delling G, Denkert C, von Minckwitz G: PARP expression in primary operable breast cancer –translational research in GeparTrio. 94. Jahrestagung der Deutschen Gesellschaft für Pathologie, Berlin, Mai 2010
Klauschen F, Loibl S, Darb-Esfahani S, Stenzinger A, Linde M, Dietel M, von Minckwitz G, Denkert C: Automated quantitative analysis of Her2 expression in immunohistochemical data in a neoadjuvant breast cancer study. 94. Jahrestagung der Deutschen Gesellschaft für Pathologie, Berlin, Mai 2010
Müller B, von Minckwitz G, Darb-Esfahani S, Eierman W, Kaufman M, Roller M, 3, Denkert C, Loibl S: Androgenrezeptor-Expression in hormonrezeptor negativen / Her2- negativen Mammakarzinomen der GeparTrio Studie. 94. Jahrestagung der Deutschen Gesellschaft für Pathologie, Berlin, Mai 2010
Darb-Esfahani S, Loibl S, Müller B, Schwedler k, Denkert C, Kantelhardt E, Budczies J, Ataseven B, Dietel M, von Minckwitz G: Biologische Tumortypen des Mammakarzinoms: Prädiktiver und prognostischer Wert bei Patientinnen mit neoadjuvanter Anthracyclin- und Taxan-haltiger Chemotherapie. 94. Jahrestagung der Deutschen Gesellschaft für Pathologie, Berlin, Mai 2010
Originalarbeiten 2009
Costa S.D, Loibl S, Kaufmann M, Zahm D.M, Hilfrich J, Huober J, Eidtmann H, du Bois A, Blohmer J.U, Eiermann W, Weiss E, Tesch H, Gerber B, Baumann K.H, Thomssen C, Breitbach G.P, Ibishi S, Jackisch C, Mehta K, von Minckwitz g, for the German Breast Group: Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: A secondary analysis of the GEPARTRIO trial data. J Clin Oncol 28(1):83-91, 2009
Engels K, du Bois A, Harter P, Fisseler-Eckhoff A, Kommoss F, Stauber R, Kaufmann M, Nekljudova V, Loibl S: VEGF-A and i-NOS Expression are Prognostic Factors in Serous Epithelial Ovarian Carcinomas after Complete Surgical Resection. J. Clin. Pathol 62(5):448-54, 2009
Darb-Esfahani S, Loibl S, Müller B.M, Roller M, Denkert C, Komor M, Schlüns K, Blohmer J.U, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G: Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res. 11(5):R69, 2009
Loibl S, Murmann C, Schwedler K, Warm M, Müller L, Heinrich G, Nekljudova V, von Minckwitz G: Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial. Cancer Chemother Pharmacol 63(5):953-8, 2009
von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh F.E, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann K. H, Clemens M.R, Duerr R, Uleer C, Andersson M, Stein R.C, Nekljudova V, Loibl S: Trastuzumab beyond progression in humen epidermal growth factor receptor 2-positive advance breast cancer: a german breast group 26/Breast international group 03-05 study. J Clin Oncol 27(12):1999-2006, 2009
Kongressbeiträge 2009 (Abstracts, Poster, Präsentationen)
St. Gallen
ICE study: Ibandronate with or without Capecitabine in Elderly Patients with Early Breast Cancer (Abstract)
ASCO
ESMO/ECCO
ZORO study: Präsentation: siehe ASCO
SABCS
Originalarbeiten 2008
Loibl S, von Minckwitz G, Harbeck N, Janni W, Elling D, Kaufmann M, Eggemann H, Nekljudova V, Sommer H, Kiechle M, Kummel S: Clinical feasibility of (neo)adjuvant taxane based chemotherapy in elderly patients: an analysis of > 4,500 patients from four german randomized breast cancer trials. Breast Cancer Res 10(5):R77, 2008
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa C.D, Jackisch C, Loibl S, Mehta K, Kaufmann M: Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 100(8):542-51, 2008
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa S.D, Jackisch C, Loibl S, Mehta K, Kaufmann M: Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 100(8):552-62, 2008
von Minckwitz G, Kümmel S, du Bois A, Eiermann W, Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa S.D, Jackisch C, Grasshoff S.T, Vescia S, Skacel T, Loibl S, Mehta K, Kaufmann M: Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/ cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 19(2):292-8, 2008
von Minckwitz G, Sinn H.P, Raab G, Loibl S, Blohmer J.U, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa S.D, Caputo A, Kaufmann M: Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 10(2):R30, 2008
Engels K, Knauer S.K, Loibl S, Harter P, Schweitzer A, Fisseler-Eckhoff A, Kommoss F, Hanker L, Nekljudova V, Hermanns I, Kleinert H, Mann W, du Bois A, Stauber R.H: NO signalling confers cytoprotectivity the surviving network in ovarian carcinomas. Cancer Res 68(13):5159-66, 2008
Abstracts 2008
von Minckwitz G, Kaufmann M, Kümmel S, Fasching P, Eiermann W, Blohmer J.U, Costa S.D, Loibl S, Volz D, Untch M: Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing hemotherapy. Cancer Res 2009, 69(Suppl.):(2). (SABCS 2008, Oral Presentation # 79)
Loibl S, Müller B, Roller M, Kronenwett R, Darb-Esfahani S, Komor M, von Toerne C, Wirtz R, von Minckwitz G, Denkert C on behalf of the German Breast Group: Local versus Central HER2 Immunohistochemistry Correlates with kinetic RT-PCR but Only Central Immunohistochemistry and RT-PCR predict Pathological Complete Response: Results from the Neoadjuvant Multicenter GeparTrio Trial. Cancer Res 2009, 69(Suppl.):(2). (SABCS 2008, Poster # 1070)
von Minckwitz G, Rezai M, Loibl S, Fasching P.A, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, Untch M for the German Breast Group and AGO Breast Group: Effect of trastuzumab on pathologic complete response rate of neoadjuvant EC-docetaxel treatment in HER2-overexpressing breast cancer: Results of the phase III GeparQuattro study. Breast Cancer Symposium, Proceeding Book 2008, Astract # 226, Page Nr. 198 (ASCO Breast 2008)
Loibl S, Murmann C, Schwedler K, Warm M, Müller L, Heinrich G, Nekljudova V, von Minckwitz G: A multicentre phase I dose finding study to investigate the combination of bendamustine with weekly paclitaxel as first or second line therapy in patients with anthracycline pretreated metastatic breast cancer – the RiTa trial. Breast Cancer Symposium, Proceeding Book 2008, Astract Nr. 178, Page Nr. 174 (ASCO Breast 2008)
von Minckwitz G, Zielinski C, Maartense E, Vogel P, Schmidt M, Eidtmann H, Cufer T, De Jongh F.E, Kaufmann M, Loibl S: Capecitabine vs. Capecitabine + trastuzumab in patients with HER-2 positive metastatic breast cancer progressing during trastuzumab treatment – the TBP phase III study (GBG 26 / BIG 3-05). Ann Oncol 19(8):63, 2008 (ESMO 2008, Abstract # 133O)
Loibl S, Murmann C, Schwedler K, Warm M, Müller L, Heinrich G, Nekljudova V, von Minckwitz G: A multicentre phase I dose finding study to investigate the combination of bendamustine with weekly paclitaxel as first or second line therapy in patients with anthracycline pretreated metastatic breast cancer – the RiTa trial. Ann Oncol 19(8):69, 2008 (ESMO 2008, Abstract # 155P)
Untch M, Fasching P.A, Bauerfeind I, Conrad U, Camara O, Fett W, Kuzeder W, Lück H, Loibl S, von Minckwitz G: PREPARE trial. A randomized phase III trial comparing preoperative, dose dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin / cyclophosphamide followed by paclitaxel darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery. J Clin Oncol 26(15S):10s, 2008 (ASCO 2008 Abstarct # 517)
von Minckwitz G, Zielinski C, Maartense E, Vogel P, Schmidt M, Eidtmann H, Cufer T, de Jongh F, Kaufmann M, Loibl S: Capecitabine vs. capecitabine + trastuzumab in patients with HER-2 positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26 / BIG 3-05). J Clin Oncol 26(15S):47s, 2008 (ASCO 2008, Abstract # 1025)
Untch M, Rezai M, Loibl S, Fasching P, Houber J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, von Minckwitz G: Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/cyclophoshamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study "GeparQuatro". Eur J Cancer 6(7):47, 2008 (EBCC Berlin 2008)
Loibl S, Ring A, von Minckwitz A, Heinrigs M, Lenhard M, Amant F, Weiss C, Augustin D, Nekljudova V, Kaufmann M: Breast cancer during pregnancy – a prospective and retrospective registry (GBG-20/BIG02-03). Eur J Cancer 6(7):68, 2008 (EBCC Berlin 2008)
Vescia S, von Minckwitz G, Loibl S, Jackisch C, Paepke S, Nestle-Kremmling C, Lux M.P, Maass N, Schmutzler R, Kaufmann M: The Giss Trial: A pilot phase randomized prevention trial of screening plus goserelin plus ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer. Eur J Cancer 6(7):72, 2008 (EBCC 2008)
Loibl S: Young woman and fertility in breast cancer. Eur J Cancer 6(7):105, 2008 (EBCC Berlin 2008)
von Minckwitz G, Rezai M, Loibl S, Fasching P, Houber J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, Untch M: Capecitabine given concomitantly or in sequence with EC ---> docetaxel as neoadjuvant treatment for early breast cancer: GeparQuatro - a GBG/AGO intergroup study. Eur J Cancer 6(7):108, 2008 (EBCC Berlin 2008)
Loibl S, Murmann C, Schwedler K, Warm M, Heinrich G, Nekljudova V, von Minckwitz G: A multicentre phase I dose finding study to investigate the combination of bendamustine with weekly paclitaxel as first or second line therapy in patients with anthracycline pretreated metastatic breast cancer – The RiTa trial. Internal Journal for Cancer Research and Treatment 31(1), 2008 (DKK Berlin 2008)
Originalarbeiten 2007
Loibl S, Schwedler K, von Minckwitz G, Strohmeier R, Mehta K, Kaufmann M: Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study. Ann Oncol 18(4):689-93, 2007
Kaufmann M, Graf E, Jonat W, Eiermann W, Vescia S, Geberth M, Conrad B, Gademann G, Albert U.S, Loibl S, von Minckwitz G, Schumacher M: A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93. Eur J Cancer 43(16):2351-8, 2007
Rody A, Karn T, Solbach C, Gaetje R, Munnes M, Kissler S, Ruckhaberle E, von Minckwitz G, Loibl S, Holtrich U, Kaufmann: The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast 16(3):235-40, 2007
Rody A, Holtrich U, Gaetje R, Gehrmann M, Engels K, von Minckwitz G, Loibl S, allo-Danebrock R, Ruckhaberle E, Metzler D, Ahr A, Solbach C, Karn T, Kaufmann M: Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin Cancer Res 13(4):1115-22, 2007
Rody A, Karn T, Gatje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhaberle E, Holtrich U, von Minckwitz G, Kaufmann: Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast 16(1):86-93, 2007
Abstracts 2007
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Houber J, Costa S, Loibl S: Inflammatory and locally advanced breast cancer respond similar to operable breast cancer to neoadjuvant chemotherapy: Results from the GEPARTRIO study. J Clin Oncol 25(18S):13s, 2007 (ASCO 2007, # 542)
Loibl S, Schmidt M, Marquart, Houber J, Bischoff J, von Minckwitz G, Mehta K, Kaufmann M: Mitomycin C in combination with capecitabine (Mi-Cap) as chemotherapy in breast cancer with extensive liver metastases and impaired hepatic function: A non-randomized multicentre phase II. J Clin Oncol 25(18S):714s, 2007 (ASCO 2007, Nr. 19597)
Mueller V, Reithdorf S, Loibl S, Komor M, Houber J, Schrader I, Conrad U, Untch M, von Minckwitz G, Pantel K: Prospective monitoring of circulating tumor cells in bresat cancer patients treated with primary systemic therapy-A translational project of the German Breast Group study GeparQuattro. J Clin Oncol 25(18S):735s, 2007 (ASCO 2007, Nr.21085)
Loibl S, Pfisterer J, Wimberger P, Kurzeder C, du Bois A, Sehouli J, Belau A, Burchardi N, Vergote I, Wagner U: Randomised, multicenter, 2-dose-level, open label, phase IIa study with the intraperitoneally infused trifunctional biospecific antibody catumaxomab (anti-EpCAM x anti CD3) to select the better dose level inplatinum refractory epithelial ovarian cancer patients. Eur J Cancer 5(4):312, 2008 (ECCO 2007, # 5005, Oral Presentation)
Reithdorf S, Loibl S, Komor M, Houber J, Schrader I, Conrad U, Untch M, von Minckwitz G, Pantel K, Mueller V: Incidence and kinetics of circulating tumor cells in breast cancer patients treated with primary systemic therapy including trastuzumab for patients with HER2-positive tumors a translational project within the study Gepar Quattro. Breast Cancer Res Tr 106(1), 2007 (SABCS 2007, Nr.5025), Page Nr. S214
Rody A, Holtrich U, Gaetje R, Engels K, von Minckwitz G, Loibl S, Gehrmann M, Ruckhaberle E, Ahr A, Solbach C, Karn T, Kaufmann M: Breast cancer classication according to stem cell-like features and its relevance for systemic adjuvant treatment decision. Breast Cancer Res Tr 106(1), 2007 (SABCS 2007, Nr.3103), Page Nr. S161
Untch M, Rezai M, Loibl S, Fasching P, Houber J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, von Minckwitz G: Evaluating the efficacy and safety of trastuzumab given concomitantly to epirubicin/ cyclophosphamide docetaxelcapecitabine as neoadjuvant treatment of HER2 verexpressing primary breast cancer. First analysis of the GBG/AGO intergroup-study GeparQuattro. Breast Cancer Res Tr 106(1), 2007 (SABCS 2007, Nr.5053), Page nr. S224
von Minckwitz G, Rezai M, Loibl S, Fasching P, Houber J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, Untch M: Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study GeparQuattro. Breast Cancer Res Tr 106(1), 2007 (SABCS 2007, Nr.79), Page Nr. S21
von Minckwitz G, Vogel P, Schmidt M, Eidtmann H, Cufer T, de Jongh F, Maartense E, Zielinski C, Andersson M, Stein R, Nekljudova V, Loibl S: Trastuzumab treatment beyond progression in patients with HER-2 positive metastatic breast cancer the TBP study (GBG 26/BIG 3-05). Breast Cancer Res Tr 106(1), 2007 (SABCS 2007, Nr.4056), Page Nr. S185
Loibl S, von Minckwitz G, Heinrigs M, Lenhard M, Amant F, Wolf I, Weiss C, Augustin D, Nekljudova V, Kaufmann M: Breast cancer during pregnancy – a prospective and retrospective registry (GBG-20/BIG02-03). ESGO 2007
von Minckwitz G, Blohmer J.U, Raab G, Steffen J, Kaufmann M, Loehr A, Gerber B, Heinrich G, Eidtmann H, Hilfrich J, Jackisch C, Costa S.D, Houber J, Bühler H, Loibl S: Prospective central assessment of HER-2 status by FISH is not a predictive factor for pathologic complete response (pCR) in 648 breast cancer patients treated preoperatively with an anthracycline / taxane based regimen in the multicenter GeparTrio trial. AACR 2007
Kontakt:
Lejla Valjevcic
Fon: +49 6102 7480-418
Fax: +49 6102 7480-118
Diese E-Mail-Adresse ist gegen Spambots geschützt! Sie müssen JavaScript aktivieren, damit Sie sie sehen können.